Public Announcements Publications. Promptly following execution of this Agreement by the Parties, either Party may issue an initial press release in such form as the Party may hereafter agree upon. Neither Party shall issue any further news release or other public announcement relating to this Agreement, including any of its terms, or to the performance of either party hereunder, without the prior written approval of the other Party, such approval not to be [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED. unreasonably withheld. Once the text or substance of any announcement has been so approved, it may be repeated without further approval.
Public Announcements Publications. 14.6.1. Coordination. AGTC and Biogen will, from time to time and at the request of the other Party, discuss the general information content relating to this Agreement that may be publicly disclosed; provided, however, that Biogen shall have no obligation to consult with AGTC with respect to any scientific publication or public announcement concerning Biogen’s Development, Manufacture, Commercialization or use of any Licensed Product (except as otherwise expressly set forth in Section 14.6.4).
Public Announcements Publications. Article 10 of the Co-Development Agreement is incorporated herein by reference, provided however that all references to “this Agreement” therein shall be deemed also to be references to this Agreement.
Public Announcements Publications. 9.5.1. Coordination; Publications. CRISPR and Vertex will, from time to time and at the request of the other Party, discuss the general information content relating to this Agreement that may be publicly disclosed; provided, however, Vertex may make scientific publications or public announcements concerning its Exploitation activities with respect to any Product Candidate or Product under this Agreement without CRISPR’s prior written approval and Vertex will have no obligation to consult with CRISPR with respect to any scientific publication or public announcement concerning Vertex’s Exploitation of any Product Candidate or Product, except as otherwise expressly set forth in this ARTICLE 9. During the Agreement Term, CRISPR may not publish, present or make any publication concerning Vertex’s Exploitation of any Product Candidate or Product without Vertex’s prior written consent, except as otherwise expressly set forth in this ARTICLE 9.
Public Announcements Publications. 8.4.1. Coordination. CRISPR will have no obligation to consult with Bayer with respect to any scientific publication or public announcement concerning CRISPR’s Research, Development, Manufacture, Commercialization or use of any Product. [***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
Public Announcements Publications. 7.5.1. Coordination. Pharmacopeia and Wyeth will, from time to time, and at the request of the other Party, discuss and agree on the general information content relating to this Agreement which may be publicly disclosed (including, without limitation, by means of any printed publication or oral presentation), provided, however, that neither Party, subject to Section 7.5.2 (Announcements) and Section 7.5.4 (Publications) below, will have any obligation to consult with the other Party with respect to any scientific publication or public announcement concerning its Development or Commercialization activities with respect to Products under this Agreement; provided, however, that, prior to the First Commercial Sale of any Product, the Lead Developer of such Product will use reasonable efforts to notify the other Party at least one (1) business day in advance of issuing any press release and at least five (5) business days in advance of any such scientific publication becoming publicly available.
Public Announcements Publications. Section 12.5.2 and Section 12.5.3 of the Agreement are hereby amended by deleting them in their entirety and replacing them with the following text:
Public Announcements Publications. During the Term, each Party (the “Publishing Party”) shall submit to the other Party (the “Non-Publishing Party”) for review and approval all proposed press releases, public filings with the SEC, academic, scientific and medical publications and public presentations that disclose previously undisclosed technical information regarding the Product, provided that each Party shall have the right to make disclosures which in its judgment are required by law, regulation, or the rules of any nationally-recognized securities exchange. Such review and approval shall be conducted for the purposes of preserving intellectual property protection and the confidentiality of trade secrets and determining whether any portion of the proposed publication or presentation containing the Confidential Information of the Non-Publishing Party should be modified or deleted. Written copies of such proposed publications and presentations (other than press releases or SEC or securities exchange filings) shall be submitted to the Non-Publishing Party as soon as reasonably practicable before submission for publication or presentation. In the case of proposed SEC filings or other securities law filings containing non-technical information regarding the Product or this Agreement, the Parties shall follow the procedures and agreements they have in place with respect to disclosures under the Collaboration Agreement, provided that each Party shall have the right to make disclosures which in its judgment are required by law, regulation, or the rules of any nationally-recognized securities exchange. Onyx and Bayer will each comply with standard academic practice regarding authorship of scientific publications and recognition of contribution of other Parties in any publications.
Public Announcements Publications. 11.5.1. Coordination. CRISPR and Vertex will, from time to time and at the request of the other Party, discuss the general information content relating to this Agreement that may be publicly disclosed; provided, however, that [***] will have no obligation to consult with [***] with respect to any scientific publication or public announcement concerning [***] Research, Development, Manufacture, Commercialization or use of any [***] or Product (except as otherwise expressly set forth in Section 12.5.3).
Public Announcements Publications
